| Literature DB >> 29516202 |
Mushtaq Ahmad1, Zahida Perveen2, Adailton J Bortoluzzi3, Shahid Hameed4, Muhammad R Shah5, Muhammad Tariq6, Ghias Ud Din2, Muhammad T Jan7, Muhammad Siddique8, Muhammad Anwar8,9.
Abstract
Apart from its numerous biological activities like antidiabetic, anti-inflammatory, antimicrobial, pyrazine moiety plays an important role in luminescent materials. Its role in luminescent materials is due to its highly electron deficient nature specially when it is in the centre along the mainstay of extended π-conjugated systems. Similarly, new liquid crystalline compounds are being made constantly where the central benzoaromatic moiety is being replaced with the heterocycles includingEntities:
Keywords: 5-Methylpyrazine-2-carbohydrazide; Iminobenzoates; Pyrazine; Pyrazine-2-carbohydrazide; Triethyl amine; X-ray crystallography
Year: 2018 PMID: 29516202 PMCID: PMC5842172 DOI: 10.1186/s13065-018-0396-3
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Scheme 1Synthesis of extended iminobenzoates with terminal pyrazine moieties
Elemental analyses data of the synthesized final compounds
| Compound | Molecular formula | Molecular weight | Calculated (%) | Found (%) | ||||
|---|---|---|---|---|---|---|---|---|
| C | H | N | C | H | N | |||
|
| C19H13FN4O3 | 364.33 | 62.64 | 3.60 | 15.38 | 62.83 | 3.78 | 15.10 |
|
| C19H13ClN4O3 | 380.78 | 59.93 | 3.44 | 14.71 | 59.64 | 3.08 | 14.89 |
|
| C19H13ClN4O3 | 380.78 | 59.93 | 3.44 | 14.71 | 60.13 | 3.21 | 14.93 |
|
| C19H13ClN4O3 | 380.78 | 59.93 | 3.44 | 14.71 | 60.30 | 3.70 | 14.84 |
|
| C19H13BrN4O3 | 425.24 | 53.67 | 3.08 | 13.18 | 53.58 | 2.90 | 13.32 |
|
| C19H13BrN4O3 | 425.24 | 53.67 | 3.08 | 13.18 | 53.79 | 3.21 | 13.35 |
|
| C20H15FN4O3 | 378.36 | 63.49 | 4.00 | 14.81 | 63.67 | 4.19 | 14.69 |
|
| C20H15ClN4O3 | 394.81 | 60.84 | 3.83 | 14.19 | 60.68 | 3.59 | 14.40 |
|
| C20H15ClN4O3 | 394.81 | 60.84 | 3.83 | 14.19 | 60.72 | 3.97 | 14.51 |
|
| C20H15ClN4O3 | 394.81 | 60.84 | 3.83 | 14.19 | 61.13 | 4.09 | 14.01 |
|
| C20H15BrN4O3 | 439.26 | 54.69 | 3.44 | 12.75 | 54.38 | 3.35 | 12.98 |
|
| C20H15BrN4O3 | 439.26 | 54.69 | 3.44 | 12.75 | 54.82 | 3.71 | 12.53 |
Fig. 1X-ray diffraction structures of compounds 4d and 4j
Crystallographic data for compounds 4d and 4j
|
|
| |
|---|---|---|
| Empirical formula | C19H13ClN4O3 | C20H15ClN4O3 |
| Formula weight | 380.78 | 394.81 |
| Temperature (K) | 200 (2) | 200 (2) |
| Wavelength (Å) | 0.71073 | 0.71073 |
| Crystal system | Triclinic | Monoclinic |
| Space group | Pī | P21/c |
| Unit cell dimensions (Å, o) | a = 5.5960 (3) | a = 22.6336 (8) |
| b = 7.3072 (4) | b = 10.9519 (4) | |
| c = 22.4039 (13) | c = 7.4045 (3) | |
| α = 95.643 (2) | ||
| β = 93.132 (2) | β = 97.2090 (10) | |
| γ = 111.325 (2) | ||
| Volume (Å3) | 845.21 (8) | 1820.93 (12) |
| Z | 2 | 4 |
| Density (calculated) (Mg/m3) | 1.496 | 1.440 |
| Absorption coefficient (mm−1) | 0.256 | 0.240 |
| F(000) | 392 | 816 |
| Crystal size (mm3) | 0.400 × 0.160 × 0.020 | 0.260 × 0.060 × 0.060 |
| Theta range for data collection (o) | 1.836 to 30.072 | 1.814 to 30.115 |
| Index ranges | − 7 ≤ h ≤ 7, − 10 ≤ k ≤ 10, | − 31 ≤ h ≤ 21, − 12 ≤ k ≤ 15, |
| − 31 ≤ l ≤ 31 | − 10 ≤ l ≤ 10 | |
| Reflections collected | 15,770 | 22,479 |
| Independent reflections | 4959 [R(int) = 0.0207] | 5369 [R(int) = 0.0268] |
| Absorption correction | Semi-empirical from equivalents | |
| Max. and min. transmission | 0.9949 and 0.9046 | 0.9857 and 0.9402 |
| Refinement method | Full-matrix least-squares on F2 | |
| Data/restraints/parameters | 4959/0/244 | 5369/0/258 |
| Goodness-of-fit on F2 | 1.028 | 1.027 |
| Final R indices [I > 2σ(I)] | R1 = 0.0392, wR2 = 0.1027 | R1 = 0.0413, wR2 = 0.1045 |
| R indices (all data) | R1 = 0.0525, wR2 = 0.1113 | R1 = 0.0577, wR2 = 0.1129 |
Fig. 2Hydrogen bonding (top) and π–π-stacking interactions (middle) for 4d and π–π-stacking interactions observed in packing analysis of 4j (bottom)